Grace Therapeutics, Inc. Derivative Liability, Current
Grace Therapeutics, Inc. (GRCE) had Derivative Liability, Current of $32.00 thousand as of 2021-12-31, per its 10-Q filed 2022-02-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2022-02-14
- 2021-12-31: Derivative Liability, Current $32.00K.
- 2021-03-31: Derivative Liability, Current $0.00.
| Period end | Derivative Liability, Current |
|---|---|
| 2021-12-31 | $32.00K 10-Q · filed 2022-02-14 |
| 2021-03-31 | $0.00 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |